Table 1 Baseline characteristics of all PGC patients
Clinical parameters | Number of Patients |
|---|---|
Age | |
 Range (yr)/Mean ± SD | 39–92/66.07 ± 12.39 |
Gender | |
 Male | 71.62% (53/74) |
 Female | 28.38% (21/74) |
Preoperative pathological diagnosis | |
 Yes | 13.51% (10/74) |
 No | 86.49% (64/74) |
Chemotherapy before onset of perforation | |
 Yes | 1.35% (1/74) |
 No | 98.65% (73/74) |
Location of cancer | |
 Upper and middle 1/3 | 16.22% (12/74) |
 Lower 1/3 | 83.78% (62/74) |
Lymph node metastasis | |
 N0 | 12.16% (9/74) |
 N1-3 | 87.84% (65/74) |
T stage | |
 T3 | 1.35% (1/74) |
 T4a | 94.59% (70/74) |
 T4b | 4.05% (3/74) |
TNM stage | |
 II-B (T3N1M0, T4a N0 M0) | 13.51% (10/74) |
 III-A/B/C(T4a-b N1-3 M0) | 45.95% (34/74) |
 IV (Tany Nany M1) | 40.54% (30/74) |
Treatments | |
 Conservative treatment | 8.11% (6/74) |
 Repair + chemotherapy | 18.92% (14/74) |
 Repair + Palliative care | 4.05% (3/74) |
 Palliative partial gastrectomy + chemotherapy | 9.46% (7/74) |
 One-stage radical gastrectomy | 5.41% (4/74) (Total gastrectomy) |
33.78% (25/74) (Subtotal gastrectomy) | |
 Two-stage radical gastrectomy | 20.27% (15/74) (Subtotal gastrectomy) |